Company intelligence / Profile preview

Basilinq

Southern California*, California, United Statesbasilinq.com ↗

Ownership: Private
Development stage: Other

Overview

Celletto™ is a novel nanomechanical gene delivery platform designed to overcome the limitations of viral and non-viral methods. It enables efficient, scalable, and cost-effective engineering of cell-based therapies by delivering genetic material into cells without compromising viability. The company positions its technology as disruptive in the field of cell and gene therapy manufacturing.

Therapeutic areas: Other
Modalities: Gene therapyCell therapyNon-viral gene delivery technology
Industry: Non-Drug Biotech

Partnerships

Not specified in public sources as of June 2025.

Beyond the preview

Go deeper on Basilinq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Basilinq.

Explore the full profile